Coty Inc.

source: coverage-next-full step: 01 type: business_model ticker: COTY company: Coty Inc. generated: 2026-05-28

Step 01 — Business Model

Key Findings

• COTY operates a licensed-fragrance + mass-color hybrid business: ~63–65% of FY25 revenue comes from Prestige (license-heavy designer fragrance houses, plus owned prestige skincare); ~35–37% comes from Consumer Beauty (mass color cosmetics, mass fragrance, and Brazil) [S1][S3].
• The value-chain logic is asset-light at the brand-IP layer (Coty does not own most prestige brand IP; it licenses it from designer houses like Burberry, Hugo Boss, Gucci, Calvin Klein, and Marc Jacobs) but asset-heavy at the formulation + fragrance-creation + packaging + global distribution layer (Coty owns the perfumer relationships, contract-manufacturing relationships, and the global retail distribution network) [S3].
• The September 2025 strategic announcement explicitly integrates Prestige Beauty + Mass Fragrance into a single global Fragrance & Beauty unit, signaling that the next form factor of Coty is a fragrance-pure-play with skincare optionality — and that Consumer Beauty (mass color) is up for partnerships, divestitures, spin-offs, or other strategic alternatives [S2].
• Net: positive for thesis. The business model becomes more focused, more defensible, and structurally exposed to the fastest-growing beauty subsegment if Consumer Beauty is carved out.

Implications for Thesis and Valuation

• The fragrance license model is scale-dependent: economic moat comes from being the operating partner of choice for designer houses that lack in-house fragrance-creation, perfumer relationships, and global distribution. Coty's ability to renew Burberry (extended in 2023) and Hugo Boss (extended in 2024) is the single most important determinant of long-term enterprise value.
• The strategic-review optionality on Consumer Beauty is the largest near-term value-creation lever outside of license renewal. A successful divestiture would simplify the equity story toward an "Inter Parfums + scale" framing (~12–14x EV/EBITDA) versus the current ~7x multiple of the conglomerate.
• The owned-brand prestige skincare push (Lancaster, philosophy, Orveda — and possibly the SKKN/Kylie portfolio long term) is the optionality at the top end but is not yet scaled enough to materially move valuation.

Objective

Describe Coty's business model — what they sell, who they sell it to, and where they sit in the beauty value chain — so downstream steps on revenue architecture (Step 03), margin (Step 04), capital allocation (Step 07), and moat (Step 10) can build on a single coherent model.

Narrative Analysis

Two-segment structure

Prestige segment (~63% of FY25 revenue, ~65% in Q3 FY26) [S1][S3]:

• Licensed prestige fragrance houses: Burberry, Hugo Boss, Calvin Klein, Gucci, Marc Jacobs, Chloé, Davidoff, Jil Sander, Tiffany & Co., Joop!, Marni, Naomi Campbell (plus newer entries). Coty negotiates multi-decade licenses (typical structure: 10–20 years with renewal options), pays a royalty to the designer house, and controls the entire fragrance creation, manufacturing, marketing, and distribution stack [S3].
• Owned prestige brands: Lancaster, philosophy, Orveda (skincare); plus the Kylie / SKKN portfolio (license/partnership with Kim Kardashian and Kylie Jenner brands) — used as the platform for prestige skincare expansion.

Consumer Beauty segment (~37% of FY25, ~35% Q3 FY26) [S1][S3]:

• Mass color cosmetics: CoverGirl, Rimmel, Max Factor, Sally Hansen, Bourjois — mostly owned IP, distributed through drug, mass, and grocery channels.
• Mass fragrance: Adidas, Mexx, Coty-owned licensed mass fragrances — distributed through mass retail.
• Brazil portfolio: Risque, Monange, Paixao, Bozzano, Biocolor — local Brazilian brands acquired in 2012 from Hypermarcas; the largest player in Brazilian nail and locally relevant in fragrance/body. Approximately $400M of FY25 revenue [S2].

Value-chain map

Revenue model

• Wholesale + retail mix: ~90%+ of revenue is wholesale to retailers (Macy's, Nordstrom, Sephora, Ulta in US; specialty + department stores internationally; mass retail for Consumer Beauty). DTC ecommerce share is growing but still a single-digit % of total revenue [S3].
• Travel retail: Material exposure (estimated 10%+ of prestige revenue), historically a high-margin channel; China travel-retail volatility was a meaningful 2024–2025 headwind [S3].
• Geographic split (FY25 approximate): EMEA largest at ~40%; Americas ~35% (US dominant); Asia-Pacific ~15%; Brazil/LatAm ~10% [S3].

The September 2025 reorganization

The "integrate Prestige + Mass Fragrance" announcement consolidates Coty's fragrance operations across price tiers into one operating engine — exploiting the fact that Coty is uniquely positioned as a top-2 player in both prestige fragrance (Burberry, Hugo Boss) and mass fragrance (Adidas, Mexx) [S2]. The thesis is that the perfumer-relationship, packaging-design, manufacturing-scale, and distribution advantages should be shared across price tiers rather than siloed.

The strategic review of Consumer Beauty (mass color + Brazil) explicitly evaluates partnerships, divestitures, spin-offs, and other actions. A spin-off would mirror what Procter & Gamble did with its beauty brands in 2016 (sold to Coty itself). A sale to a strategic (e.g., L'Oréal, Henkel) or a financial sponsor (KKR has appetite for beauty after acquiring Wella) are both plausible paths [S2].

Evidence and Sources

Detail in COTY_financials/sec_filings/10K_FY2025_summary.md and COTY_financials/presentations/investor_presentation_2025.md.

Assumption Register Updates

• A04 (Prestige ~63% of FY25 revenue) — Fact, High sensitivity (drives the segment-level valuation logic)

Tables and Calculations

Segment economic profile (FY25 illustrative, from 10-K disclosure)

(Approximations; exact segment profit varies by reported vs. adjusted basis. See COTY_financials/other/consensus.md for the company-reported adj. EBITDA of ~$1.08B at 18.4% margin.)

Brand portfolio at a glance

Open Questions and Data Gaps

1. License expiry schedule. Coty does not publicly disclose a full schedule of remaining license terms. Step 10 (moat) will treat this as a key risk.
2. DTC ecommerce share growth. Disclosed only in passing; not quantified.
3. Per-brand revenue. Not disclosed below segment level except for marquee licenses.

Next-Step Dependencies

Step 02 will use the segment + geographic mix to size the addressable market by category. Step 03 will pull the quarterly segment trajectory.

Source Index

Note: Earnings-call transcripts were intentionally not loaded (coverage-next-full path). Management commentary in this step is sourced from 8-K earnings releases (prepared-remarks summaries), press releases, and the FY25 10-K MD&A.

source: coverage-next-full step: 12 type: catalysts_bull_bear ticker: COTY company: Coty Inc. generated: 2026-05-28

Step 12 — Catalysts / Bull vs Bear Debate

Key Findings

• The defining near-term catalyst is the September-2025 strategic review of Consumer Beauty — the binary that converts COTY from a slow-growth conglomerate into either (a) a focused prestige-fragrance pure-play trading nearer to IPAR multiples (~12–14x EV/EBITDA) or (b) an unsuccessful carve-out attempt that resets the equity narrative [S1][S2].
• Bull thesis is structural (fragrance category secular growth, scale + counter-positioning moat, deleveraging completion, dividend reinstatement) rather than a quick-cycle trade. Bear thesis is operational and near-term (mass-color erosion, tariff GM compression, license-renewal binary risk, controlling-shareholder concentration) [S2][S3].
• The debate cannot be resolved on filings alone. Without earnings-call transcript color, the qualitative view of "is management confident?" must be inferred from (a) the Aug-2025 CEO open-market purchase of ~272.5k shares at ~$5.50–6.50, (b) the Q3 FY26 8-K's willingness to raise EPS guidance while lowering EBITDA, and (c) the willingness to put Consumer Beauty under strategic review at all [S4][S5].
• Net: actionable in both directions. The bull case offers a credible path to ~$8–10 over 18–24 months; the bear case implies $2.50–3.00 if the strategic review fails and Prestige weakness extends.

Implications for Thesis and Valuation

• The bull case multiple (12–14x EBITDA) and the bear case multiple (5–6x EBITDA) bracket the entire equity range. Per-share value is enormously sensitive to which case plays out — this is the dispersion that makes COTY an opportunistic position rather than a core holding (see Step 18).
• The Q1 FY27 print (calendar Q3 2026) is the highest-conviction catalyst window: first cleanly post-tariff comparison + first quarter that should reveal strategic-review direction.
• License renewals are the single most important non-modeling discontinuity. The next material renewal events (Marc Jacobs estimated 2027–2030 window; Calvin Klein later) are far enough out to be a watch-item, not a Year-1 forecast input.

Objective

Stage the bull/bear analyst debate around COTY's investment case using the filings-and-consensus path (no transcripts loaded). Identify the catalysts that move the equity in each direction, and end with the 3-bullet bull and 3-bullet bear cases that feed /complete-coverage Step 15 and the public /stocks/{ticker} page.

Narrative Analysis

How the debate sets up without transcripts

Coverage-next-full deliberately excludes earnings-call transcripts. The Step 12 analyst-debate is therefore reconstructed from:

1. 8-K prepared remarks summaries (the press-release portion that includes management quotes and forward-looking commentary) [S3].
2. Consensus notes (analyst expectations, range, and rating distribution) [S4].
3. Recent news flow (Wella divestiture close Dec-2025; KKR full exit Q4-2025; Sept-2025 strategic review announcement) [S2][S5].
4. Insider behavior (Aug-2025 CEO open-market buy is the single strongest signal observed) [S6].

Where the debate would benefit from transcript color (e.g., tone on tariff pass-through, license-renewal confidence, M&A appetite), this step flags the gap rather than fabricating.

The bull case (structural fragrance pure-play)

The bear case (mass-color erosion + tariff + binary risk)

Catalyst calendar (next 18 months)

What's priced in (from consensus)

Consensus FY26 EPS ~$0.28 vs. company guide $0.33–$0.35; analyst PT range $4–$7 (median $5–$6) on a $3.74 May-2026 spot. This implies:

• Street treats the Q3 FY26 EPS raise with skepticism (consensus below guide).
• Street is pricing in some strategic-review unlock but not the full pure-play re-rate.
• Street is pricing in continued license renewals (no haircut for renewal risk).

The variant view (developed in Step 16) is that Street is under-pricing the strategic-review optionality and over-emphasizing near-term mass-color drag.

The "if I am wrong" lens

Each side of the debate has a clean falsification trigger:

• Bull case falsified if: Consumer Beauty strategic review concludes without a transaction (Dec-2026 or beyond), or a material license is lost at renewal, or tariff regime escalates further.
• Bear case falsified if: Consumer Beauty divestiture lands at ≥1.5x sales, or CEO continues open-market buying through 2026, or Prestige LFL turns clearly positive by Q1 FY27.

Evidence and Sources

Detail in COTY_financials/other/consensus.md, COTY_financials/presentations/investor_presentation_2025.md, COTY_financials/sec_filings/10K_FY2025_summary.md, COTY_financials/proxy/insider_transactions.md, and COTY_financials/industry/market_overview.md. Earnings-call transcripts were intentionally not loaded; management-tone color is sourced from 8-K prepared remarks and press releases only.

Assumption Register Updates

• A27 (Strategic review outcome timing CY2026) — Estimate, High sensitivity
• A28 (License-renewal cycle clustering 1–2 majors per year) — Estimate, High sensitivity

(Both entries already present in COTY_assumption_register.md; no new entries this step.)

Tables and Calculations

Bull / Bear EBITDA fan (rough framing for /complete-coverage Step 15)

(Approximate framing only. /complete-coverage Step 14 will produce the formal DCF + multiples grid; Step 15 will assign probabilities and an expected value.)

Catalyst probability framing (analyst-debate working hypothesis)

(Probabilities are working hypotheses for the analyst debate; /complete-coverage Step 15 will refine these into an expected-value scenario tree.)

Open Questions and Data Gaps

1. Management's confidence on Q4 FY26 / FY27 inflection — would benefit from earnings-call transcript color; flagged for /complete-coverage to consider whether re-running with transcripts is warranted.
2. License-renewal calendar — Coty does not publish; market color is the only source.
3. Strategic-review divestiture process — Coty has not disclosed timeline beyond "actively pursuing."

Next-Step Dependencies

Step 16 will sharpen the variant view vs. consensus. Steps 17 and 18 will close out institutional positioning and portfolio sizing. The 3-bullet bull and 3-bullet bear summaries below feed /complete-coverage Step 15 (scenarios) and the public /stocks/{ticker} page.

Source Index

Note: Earnings-call transcripts were intentionally not loaded (coverage-next-full path). Management tone, Q&A color, and forward-looking commentary nuance are not captured here.

Bull Case — 3 bullets

• Strategic-review unlock + multiple re-rate. A Consumer Beauty divestiture at 1.5x sales (~$2.4B proceeds) accelerates deleveraging to <2x, lifts consolidated gross margin 200–400 bps, and re-rates the residual fragrance-led business toward Inter Parfums' 12–14x EV/EBITDA multiple from today's ~7x — a doubling of the equity from a $3.74 base. [S1][S2]
• Fragrance category secular winner + scale moat. Global fragrance is growing ~7.4% CAGR (fastest major beauty subsegment), and COTY is #2 globally with ~$3.7B of prestige fragrance scale. Scale + counter-positioning (designer houses prefer to license operationally complex global distribution) sustain a durable ~250–300 bps ROIC-over-WACC spread. [S7]
• Deleveraging + CEO insider buy + Wella back-end. Net leverage 8x → 3.0x → 2.0x target by CY27; CEO Sue Nabi bought ~272,500 shares open-market in Aug 2025 (no open-market sales since 2020 hire); Wella back-end participation (45% of KKR's eventual exit) is a free option that consensus is not pricing. [S3][S6]

Bear Case — 3 bullets

• Consumer Beauty drag + tariff structural reset. Q3 FY26 Consumer Beauty LFL -10% vs. Prestige -5%; US tariffs on EU-manufactured fragrance flagged as -100 to -200 bps Q4 GM compression (~$50–100M annualized). If the strategic review fails to find a buyer at reasonable multiples and tariff regime persists, COTY is saddled with mass-color erosion plus a permanently higher cost base — bear-case EBITDA $700–800M implies ~$2.50–3.00/share. [S3]
• License-renewal binary risk. COTY does not disclose the license-expiry schedule. Recent renewal-cycle precedents include the loss of Lacoste (to IPAR, 2019) and Roberto Cavalli — renewals are not automatic. Losing a top-5 license (Hugo Boss / Burberry / Calvin Klein / Gucci / Marc Jacobs) would remove ~$100–200M of EBITDA and 10–20% of equity value at once. [S8]
• JAB controlling-stake + impairment overhang. JAB Holdings controls ~50% of Class A and board majority — no public-shareholder check on strategic decisions. $4.06B goodwill + $3.21B intangibles = ~$7.3B of soft assets vs. $3.8B equity, and the 2019–2020 $5B P&G Beauty cumulative writedown precedent is unrebutted. A Consumer Beauty divestiture below carry value would trigger fresh impairments. [S9][S10]